Table 3. Cell cycle distribution of 16HBE with knockdown of SELENBP1 and controls after repeated treatment with 1 µm B[a]P or DMSO for 18 weeks.
Cell lines | Number of cell (%) | ||
G0/G1 | S | G2/M | |
16HBE+DMSO | 70.02±4.67 | 18.58±3.48 | 11.39±1.63 |
16HBE/pLKO.1+DMSO | 69.10±3.51 | 19.64±2.87 | 11.25±1.65 |
16HBE/pLKO.1-SELENBP1-shRNA+ DMSO | 65.79±3.59 | 21.96±2.58 | 12.25±2.22 |
16HBE+ B[a]P | 67.94±2.15 | 19.10±2.44 | 12.96±2.13 |
16HBE/pLKO.1+ B[a]P | 67.25±4.20 | 19.64±2.58 | 13.11±1.81 |
16HBE/pLKO.1− SELENBP1-shRNA+ B[a]P | 50.56±5.24* | 35.75±4.49* | 13.69±1.55 |
P<0.05 by T-test, 16HBE/pLKO.1-SELENBP1-shRNA+B[a]P vs. 16HBE/pLKO.1+B[a]P, 16HBE+ B[a]P, and 16HBE/pLKO.1-SELENBP1-shRNA+B[a]P vs. 16HBE +DMSO.